GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims

Once-daily dosing provides a convenience advantage over the other inhaled corticosteroid/long-acting beta-agonist combination products on the COPD market: GlaxoSmithKline’s own Advair and AstraZeneca’s Symbicort.